MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
2.920
-0.110
-3.63%
After Hours: 2.920 0 0.00% 16:10 06/25 EDT
OPEN
3.040
PREV CLOSE
3.030
HIGH
3.150
LOW
2.870
VOLUME
3.70M
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.260
MARKET CAP
476.12M
P/E (TTM)
-1.4907
1D
5D
1M
3M
1Y
5Y
1D
Cabaletta Bio Hits Reset on RESET-MS Trial, Narrowing Near-Term Upside in Multiple Sclerosis
TipRanks · 19h ago
Weekly Report: what happened at CABA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Report: what happened at CABA last week (0608-0612)?
Weekly Report · 06/15 09:11
Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Anixa Biosciences (ANIX)
TipRanks · 06/11 13:30
Cabaletta Bio Shareholders Approve Share Increase and Directors
TipRanks · 06/11 11:36
Cabaletta Bio shareholders approve increase in authorized common shares to 600 million
PUBT · 06/11 11:02
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Cabaletta Bio (CABA) and Hinge Health, Inc. Class A (HNGE)
TipRanks · 06/08 13:20
Weekly Report: what happened at CABA last week (0601-0605)?
Weekly Report · 06/08 09:10
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.